Hide This

FREEHER HealthToolkit

HER Health Toolkit

Sign up for EmpowHER updates and you'll receive our
FREE HER Health Toolkit

Chronic Myelogenous Leukemia

Get Email Updates

Related Topics

Chronic Myelogenous Leukemia Guide

Maryann Gromisch RN Guide

Have a question? We're here to help. Ask the Community.

ASK

Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!

ask: MY BCR_ABL is near to 97% can it be reduce by using glivec? And when i should do my BCR-Abl .

By Arshad Khan
 
Rate This

Add a Comment4 Comments

Arshad Khan

i am still waiting for your answar.. plz inform me as soon as possible
thanks
arshad khan

December 13, 2012 - 9:50pm
Maryann Gromisch RN Guide (reply to Arshad Khan)

Hello Arshad Khan,

Supporting Susan's reply, this is a question that you should be asking your physician. We do not know your medical history nor the these specifics of your condition and current treatment

I can offer general information.

BCR-ABL is an abnormal gene found in most people with chronic myelogenous leukemia(CML) and in some people with acute lymphoblastic leukemia (ALL). The BCR-ABL gene is created when two different genes join together that normally aren't connected. Monitoring how active the BCR-ABL gene is can tell you if certain treatments are working to control your leukemia.

Thinking logically, if in your case, the BCR-ABL level is at 97%, current treatment is not controlling your leukemia. But, I must stress, this is something your physician must confirm.

You asked about glivec. The correct name is Gleevec.

Once a Philadelphia chromosome, which is another name for the BCR-ABL gene, is diagnosed in someone with CML or ALL, the first treatment is usually a drug called imatinib (Gleevec®). Imatinib is a "targeted" therapy that directly blocks the specific protein that is made by the BCR-ABL gene. This leads to lower numbers of abnormal white blood cells so healthy cells can survive.

Imatinib is very effective and has been shown repeatedly to work better for most people than older medications like interferon. About two-thirds of people with CML responded well to imatinib within 12 months of treatment. After 5 years of treatment almost 90% of people with CML had reduced BCR-ABL activity. A few people, about 5% to10%, don't respond to imatinib or become resistant to it. These people can take dasatinib (Sprycel®) or nilotinib (Tasigna®), which are similar drugs. This group of drugs are called tyrosine kinase inhibitors.

I hope this information is helpful and will guide you in having a conversation with your physician about your condition and treatment options.

Maryann

December 18, 2012 - 5:37pm
EmpowHER Guest
Anonymous (reply to Maryann Gromisch RN)

thanks ur imformation was very helpful thanks once again

December 20, 2012 - 8:22am
Susan Cody HERWriter Guide

Hi Arshad Khan

This is medical advice that needs to be answered by your own doctor but I will see if one of our nurses can help you. Thanks for your patience.

Susan

December 13, 2012 - 1:09pm
Image CAPTCHA
Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

All user-generated information on this site is the opinion of its author only and is not a substitute for medical advice or treatment for any medical conditions. Members and guests are responsible for their own posts and the potential consequences of those posts detailed in our Terms of Service.

Improved

1771 Health

Changed

674 Lives

Saved

535 Lives
6 lives impacted in the last 24 hrs Learn More

Take Our Featured Health Poll

Do your teens have their own cellphones?:
View Results